Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?

Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, Parving HH.

J Hypertens. 2013 Aug;31(8):1646-52. doi: 10.1097/HJH.0b013e328362217c.

PMID:
23743807
2.

Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.

van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, van den Meiracker AH, Danser AH.

J Hypertens. 2011 Nov;29(11):2147-55. doi: 10.1097/HJH.0b013e32834bbcbf.

PMID:
21941204
3.

Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?

Hollenberg NK, Fisher ND, Nussberger J, Moukarbel GV, Barkoudah E, Danser AH.

J Hypertens. 2011 Dec;29(12):2454-61. doi: 10.1097/HJH.0b013e32834c627a.

4.

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.

Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH.

Diabetes Care. 2009 Oct;32(10):1873-9. doi: 10.2337/dc09-0168. Epub 2009 Jul 8.

5.

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.

Krone W, Hanefeld M, Meyer HF, Jung T, Bartlett M, Yeh CM, Rajman I, Prescott MF, Dole WP.

J Hum Hypertens. 2011 Mar;25(3):186-95. doi: 10.1038/jhh.2010.38. Epub 2010 Apr 8.

PMID:
20376075
6.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

7.

Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.

Fogari R, Mugellini A, Zoppi A, Preti P, Maffioli P, Perrone T, Derosa G.

Expert Opin Pharmacother. 2013 Mar;14(4):371-84. doi: 10.1517/14656566.2013.772981. Epub 2013 Feb 17.

PMID:
23414196
8.

Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.

Yoshida S, Ishizawa K, Ayuzawa N, Ueda K, Takeuchi M, Kawarazaki W, Fujita T, Nagase M.

Clin Exp Nephrol. 2014 Aug;18(4):593-9. doi: 10.1007/s10157-013-0893-6. Epub 2013 Oct 24.

PMID:
24154707
9.

Aliskiren and valsartan combination therapy for the management of hypertension.

Epstein BJ.

Vasc Health Risk Manag. 2010 Sep 7;6:711-22. Review.

10.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.

11.

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Hans-Henrik P.

J Renin Angiotensin Aldosterone Syst. 2012 Mar;13(1):118-21. doi: 10.1177/1470320311417272. Epub 2011 Aug 8.

PMID:
21824990
12.
13.

Urinary markers of intrarenal renin-angiotensin system activity in vivo.

Roksnoer LC, Verdonk K, van den Meiracker AH, Hoorn EJ, Zietse R, Danser AH.

Curr Hypertens Rep. 2013 Apr;15(2):81-8. doi: 10.1007/s11906-012-0326-z. Review.

PMID:
23296471
14.

Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.

Rao MS.

J Assoc Physicians India. 2010 Feb;58:102-8. Review.

PMID:
20653151
15.

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.

Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A.

Am J Hypertens. 2007 Jan;20(1):11-20.

PMID:
17198906
16.

Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.

Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L.

Hypertension. 2008 May;51(5):1306-11. doi: 10.1161/HYPERTENSIONAHA.108.110932. Epub 2008 Apr 7.

17.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
18.

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J; ATMOSPHERE Investigators.

Eur J Heart Fail. 2011 Jan;13(1):107-14. doi: 10.1093/eurjhf/hfq212.

19.
20.

Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease.

Li SY, Chen YT, Yang WC, Tarng DC, Lin CC, Yang CY, Liu WS.

BMC Nephrol. 2012 Aug 23;13:89. doi: 10.1186/1471-2369-13-89.

Items per page

Supplemental Content

Write to the Help Desk